SCHEMBL2371784

SCHEMBL2371784

N#Cc1ccc(Nc2nccc3nc(-c4c(Cl)cc(C#N)cc4Cl)[nH]c23)nc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYK2 P29597 14/20 0.55
JAK2 O60674 13/20 0.55
CDK2 P24941 2/20 0.52
JAK1 P23458 1/20 0.52
CDK9 P50750 1/20 0.52
JAK3 P52333 1/20 0.52
IDH1 O75874 1/20 0.36
RHEB Q15382 1/20 0.35
PRKCI P41743 1/20 0.35
CCNB2 O95067 1/20 0.34
CDK1 P06493 1/20 0.34
CCNB1 P14635 1/20 0.34
RPS6KB1 P23443 1/20 0.34
GSK3A P49840 1/20 0.34
GSK3B P49841 1/20 0.34
LIMK1 P53667 1/20 0.34
TAOK1 Q7L7X3 1/20 0.34
CCNB3 Q8WWL7 1/20 0.34
SLK Q9H2G2 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2371984 0.92 TYK2 (0.54) TYK2JAK2CDK2JAK1CDK9
SCHEMBL2371760 0.91 TYK2 (0.52) TYK2JAK2CDK2JAK1CDK9
SCHEMBL2372014 0.89 TYK2 (0.49) TYK2JAK2CDK2JAK1CDK9
SCHEMBL2372458 0.88 JAK2 (0.60) TYK2JAK2CDK2JAK1CDK9
SCHEMBL2372755 0.87 TYK2 (0.55) TYK2JAK2CDK2JAK1CDK9
SCHEMBL2371416 0.86 TYK2 (0.60) TYK2JAK2CDK2JAK1CDK9
SCHEMBL14857966 0.86 TYK2 (0.72) TYK2JAK2CDK2JAK1CDK9
SCHEMBL2371427 0.85 JAK2 (0.48) TYK2JAK2CDK2JAK1CDK9
SCHEMBL2372867 0.85 TYK2 (0.73) TYK2JAK2CDK2JAK1CDK9
SCHEMBL2371401 0.84 TYK2 (0.56) TYK2JAK2CDK2JAK1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130096104-A1 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2013-04-18 US disclosed
US-20130096104-A1 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2013-04-18 US disclosed
US-20130096104-A1 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2013-04-18 US disclosed
EP-2547338-A2 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. Hoffmann-La Roche AG (CH) 2013-01-23 EP disclosed
WO-2011113802-A2 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2011-09-22 WO disclosed
WO-2011113802-A2 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096104-A1 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE TYK2, IRAK1, IRAK4 TYK2 1/4885JAK2 6/4885CDK2 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.